Study protocol for THINK : a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types [PDF]
, 2017 Introduction: NKR-2 are autologous T cells genetically modified to express a chimeric antigen receptor (CAR) comprising a fusion of the natural killer group 2D (NKG2D) receptor with the CD3 zeta signalling domain, which associates with the adaptor ...
Aftimos, Philippe +15 more
core +1 more source
Practical aspects of CAR-T cell therapy
Klinicka onkologie, 2022 Chimeric antigen receptor (CAR) T cell therapy has been gradually building its position in the treatment of hematological malignancies. Currently, there are three types of autologous anti-CD19 CAR-T cells approved for the treatment of selected relapsed B cell non-Hodgkins lymphomas and acute B-lymphoblastic leukemia in the Czech Republic.
Mihályová, Jana +7 more
openaire +2 more sources
Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases. [PDF]
, 2018 One major hurdle to the success of adoptive T-cell therapy is the identification of antigens that permit effective targeting of tumors in the absence of toxicities to essential organs.
Abraham, Tara S. +9 more
core +1 more source
Cell TransplantationA significant proportion of patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) exhibit no response to chimeric antigen receptor (CAR) T-cell therapy or suffer from disease progression thereafter.
Xin Li +6 more
doaj +1 more source
Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer. [PDF]
, 2017 INTRODUCTION: Colorectal cancer remains the second leading cause of cancer death in the United States, and new strategies to prevent, detect, and treat the disease are needed.
Aka, Allison A. +5 more
core +2 more sources
Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia [PDF]
, 2019 The majority of adult patients affected by B-cell acute lymphoblastic leukemia (B-ALL) will relapse after an initial response, while approximately 20% will display primary resistant disease. Patients suffering from relapsed/refractory B-ALL have a very
Lanza, Francesco +2 more
core +1 more source
Application of CAR-T cell therapy targeting mesothelin in solid tumor treatment
Discover OncologyChimeric antigen receptor (CAR)-T-cell therapy is one of the most effective immunotherapies. CAR-T-cell therapy has achieved great success in the treatment of hematological malignancies. However, due to the characteristics of solid malignant tumors, such
Qiuhong Chen, Yang Sun, Hua Li
doaj +1 more source
Rejection of Experimental Hodgkins Lymphoma by T-cells Engineered with a CD19 Chimeric Antigen Receptor [PDF]
, 2012 T cells engineered to express chimeric receptors combining an external antibody binding domain with the CD3ζ T cell receptor (TCR) internal domain for triggering cell activation are being used for immunotherapeutic targeting of tumour cells in a non-HLA ...
Cheadle, Eleanor +5 more
core +1 more source
Practical issues in CAR T-cell therapy
Blood Research, 2023 Chimeric antigen receptor (CAR) T-cell therapy presents a revolutionary advancement in personalized cancer treatment. During the production process, the patient's own T-cells are genetically engineered to express a synthetic receptor that binds to a tumor antigen.
openaire +2 more sources
Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy. [PDF]
, 2018 Malignant gliomas carry a dismal prognosis. Conventional treatment using chemo- and radiotherapy has limited efficacy with adverse events. Therapy with genetically engineered T-cells, such as chimeric antigen receptor (CAR) T-cells, may represent a ...
Almeida, Neil D +4 more
core